retatrutide phase 2 trial new england journal of medicine approval: FDA status, clinical results, and when it could be available Retatrutide Delivers Significant Hemoglobin A1C

For patients first prescribed an ADM in June 2025, 72.2% filled a GLP-1 RA within 60 days

Qualifying comorbidities include type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and established cardiovascular disease

A major real-world study published in early 2026 led by researchers at Johns Hopkins Bloomberg School of Public Health and analysing electronic health records from approximately 175,000 people with T1D in the US found that those taking GLP-1 drugs had a roughly 15% lower five-year risk of major cardiovascular events and a 19% lower risk of end-stage kidney disease, without any increase in hospitalisation for DKA or severe hypoglycemia

AGA rapid clinical practice update on the management of patients taking GLP-1 receptor agonists prior to endoscopy: communication

Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory and antioxidant action in type 2 diabetes

Both are GLP-1 medications that are FDA-approved for Type 2 diabetes and weight loss, but how they work differs Image content: This image is available to view online